Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

MLA

Verweij, Jaap, et al. “Progression-Free Survival in Gastrointestinal Stromal Tumours with High-Dose Imatinib: Randomised Trial.” Lancet (London, England), vol. 364, no. 9440, Sept. 2004, pp. 1127–34. EBSCOhost, https://doi.org/10.1016/S0140-6736(04)17098-0.

APA

Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C. W., Van Glabbeke, M., Bertulli, R., & Judson, I. (2004). Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (London, England), 364(9440), 1127–1134. https://doi.org/10.1016/S0140-6736(04)17098-0

Chicago

Verweij, Jaap, Paolo G Casali, John Zalcberg, Axel LeCesne, Peter Reichardt, Jean-Yves Blay, Rolf Issels, et al. 2004. “Progression-Free Survival in Gastrointestinal Stromal Tumours with High-Dose Imatinib: Randomised Trial.” Lancet (London, England) 364 (9440): 1127–34. doi:10.1016/S0140-6736(04)17098-0.